share_log

Allarity Therapeutics | 10-Q: Q3 2024 Earnings Report

Allarity Therapeutics | 10-Q: Q3 2024 Earnings Report

Allarity Therapeutics | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/15 05:25

Moomoo AI 已提取核心信息

Allarity Therapeutics reported a net loss of $17.1 million for Q3 2024, compared to $10.2 million in Q3 2023. The company recorded a significant $9.7 million impairment charge on its stenoparib intangible assets after halting enrollment in the ongoing Phase 2 trial. Revenue remained minimal as the company continues to focus on research and development activities.Research and development expenses decreased to $4.2 million for the nine months, down from $4.5 million in the prior year period, while general and administrative expenses declined to $6.0 million from $7.8 million. The company strengthened its cash position to $18.5 million as of September 30, 2024, through ATM offerings that generated net proceeds of $33.1 million during the nine-month period.Looking ahead, management believes current cash reserves are sufficient to fund operations for at least the next 12 months. The company is now focusing on developing a follow-on trial for stenoparib with FDA regulatory intent, while facing ongoing challenges including an SEC investigation and a class action lawsuit related to previous disclosures about its Dovitinib NDA.
Allarity Therapeutics reported a net loss of $17.1 million for Q3 2024, compared to $10.2 million in Q3 2023. The company recorded a significant $9.7 million impairment charge on its stenoparib intangible assets after halting enrollment in the ongoing Phase 2 trial. Revenue remained minimal as the company continues to focus on research and development activities.Research and development expenses decreased to $4.2 million for the nine months, down from $4.5 million in the prior year period, while general and administrative expenses declined to $6.0 million from $7.8 million. The company strengthened its cash position to $18.5 million as of September 30, 2024, through ATM offerings that generated net proceeds of $33.1 million during the nine-month period.Looking ahead, management believes current cash reserves are sufficient to fund operations for at least the next 12 months. The company is now focusing on developing a follow-on trial for stenoparib with FDA regulatory intent, while facing ongoing challenges including an SEC investigation and a class action lawsuit related to previous disclosures about its Dovitinib NDA.
Allarity Therapeutics在2024年第三季度报告净亏损1710万，比较2023年第三季度的1020万有所增加。该公司在停止进行阶段二试验的招募后，对其stenoparib无形资产计提了970万的重大减值损失。营业收入保持在较低水平，因为公司继续专注于研发活动。研发费用在九个月内减少至420万，而去年同期为450万；同时，管理费用从780万下降至600万。截止2024年9月30日，公司的现金状况加强至1850万，这主要得益于ATm发行，期间净收益达到3310万。展望未来，管理层认为当前的现金储备足以支持至少接下来的12个月的运营。该公司目前正致力于开发一个针对stenoparib的后续试验，旨在获得FDA的监管意向，同时面临包括SEC调查和一项与前期关于Dovitinib NDA的披露相关的集体诉讼等持续挑战。
Allarity Therapeutics在2024年第三季度报告净亏损1710万，比较2023年第三季度的1020万有所增加。该公司在停止进行阶段二试验的招募后，对其stenoparib无形资产计提了970万的重大减值损失。营业收入保持在较低水平，因为公司继续专注于研发活动。研发费用在九个月内减少至420万，而去年同期为450万；同时，管理费用从780万下降至600万。截止2024年9月30日，公司的现金状况加强至1850万，这主要得益于ATm发行，期间净收益达到3310万。展望未来，管理层认为当前的现金储备足以支持至少接下来的12个月的运营。该公司目前正致力于开发一个针对stenoparib的后续试验，旨在获得FDA的监管意向，同时面临包括SEC调查和一项与前期关于Dovitinib NDA的披露相关的集体诉讼等持续挑战。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    多家机构看多！中国资产将全面重估：你会如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 🎙️讨论： 1. Deepseek引爆中国资产上涨，后市你怎么看？ 2. 多家中国企业1月表现提升，你更看好谁？ 展开
    中国的资产重估引发了讨论：mooer们在买什么？